22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

F. Cappuzzo, B. Coudert, R. Wierzbicki, K. Park, F. Custers, G.A. Curbera, G. Giaccone, W. Hilbe, G. Klingelschmitt, T.E. Ciuleanu
  • European Journal of Cancer Supplements, September 2009, Elsevier
  • DOI: 10.1016/s1359-6349(09)72057-9

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1359-6349(09)72057-9

The following have contributed to this page: Dr Federico Cappuzzo